NEW YORK (GenomeWeb News) – The drug developer Abbott has tapped Oncomethylome to profile tumors for its cancer drug research efforts, Oncomethylome said today.
 
Oncomethylome will use its high-throughput DNA methylation platform to test its biomarkers on biological samples provided by Abbot, the company said.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.